title: Preoperative care of infants with nephroblastoma. The International Society of Pediatric Oncology 6 experience.
abstract: The International Society of Pediatric Oncology (SIOP) recommends preoperative treatment in the management of eligible patients with Wilms' tumor. Until 1980, children younger than 12 months of age (infants) at diagnosis had been excluded from the SIOP trials. SIOP 6, conducted from 1980 to 1987, was the first SIOP study to include infants older than 6 months of age. This retrospective analysis of 145 infants registered to SIOP 6 demonstrates that in infants older than 6 months and having favorable histology (FH), a two-drug preoperative chemotherapy (CT) regimen of 4 weeks significantly ameliorated stage distribution as determined at delayed surgery but did not affect a good outcome. However, the CT dose utilized in SIOP 6 resulted in an unacceptable toxicity in this age group, and SIOP 9, the new SIOP study of Wilms' tumor, recommends a reduced dose of CT in infants. Preoperative CT is not recommended in infants younger than 6 months of age. Specifically, the high incidence (29%) of mesoblastic nephroma in this age group does not justify such an approach. Histopathologic diagnosis should be obtained in these patients before any treatment.
authors.affiliation: Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.
authors.forename: M J
authors.initials: MJ
authors.lastname: Coppes
authors.forename: M F
authors.initials: MF
authors.lastname: Tournade
authors.forename: J
authors.initials: J
authors.lastname: Lemerle
authors.forename: S
authors.initials: S
authors.lastname: Weitzman
authors.forename: A
authors.initials: A
authors.lastname: Rey
authors.forename: D
authors.initials: D
authors.lastname: Burger
authors.forename: M
authors.initials: M
authors.lastname: Carli
authors.forename: P A
authors.initials: PA
authors.lastname: Voûte
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008495:Medical Oncology; D009367:Neoplasm Staging; D010372:Pediatrics; D011300:Preoperative Care / Q000592:standards*; D011379:Prognosis; D012189:Retrospective Studies; D012955:Societies, Medical; D014750:Vincristine / Q000008:administration & dosage; D009396:Wilms Tumor / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D003609:Dactinomycin; D014750:Vincristine